Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

PFIZER INC : Other Events (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 06:48am EDT

Item 8.01 Other Events On December 7, 2018, Pfizer Inc. ("Pfizer") issued a notice for the redemption in full of all €1,141,300,000 aggregate principal amount outstanding of its 5.750 per cent. Notes due 2021 (ISIN: XS0432071131; COMMON CODE: 043207113) (the "Notes").

The Notes will be redeemed on January 9, 2019 at a "make-whole" redemption price as set forth in the indenture, as supplemented, pursuant to which the Notes were issued. On the redemption date, the redemption price will become due and payable on the Notes and, unless Pfizer defaults in the payment of the redemption price, interest on the Notes will cease to accrue on and after the redemption date. The notice of redemption specifying the terms, conditions and procedures for the redemption is available through The Bank of New York Mellon, located at 240 Greenwich St., New York, New York 10286, as paying agent for the Notes. The foregoing does not constitute a notice of redemption for the Notes.

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
09:28aPFIZER : Verily partners with pharma giants, promising to transform clinical res..
AQ
06:56aSANOFI : Verily signs up four big pharmas to its clinical trials platform
AQ
06:37aPFIZER : Alphabet's Verily teams with pharma companies to improve clinical trial..
AQ
04:37aPFIZER : Googles life sciences sister plugs Big Pharma into the mainstream in a ..
AQ
04:37aPFIZER : Novartis, Otsuka, Pfizer, Sanofi commit to new trials on Verily's digit..
AQ
05/22PFIZER : Description Statement of Ownership
PU
05/20PFIZER : Confirms Initiation of EU Review of Tofacitnib with Interim Recommendat..
PU
05/18PFIZER : Eczema Candidate Meets All Goals In Phase III Study
AQ
05/17PFIZER : confirms initiation of EU review of Tofacitinib with interim recommenda..
PU
05/17PFIZER : new JAK inhibitor could come after your eczema market
AQ
More news
Financials ($)
Sales 2019 53 201 M
EBIT 2019 19 478 M
Net income 2019 13 317 M
Debt 2019 32 207 M
Yield 2019 3,40%
P/E ratio 2019 17,46
P/E ratio 2020 15,94
EV / Sales 2019 4,99x
EV / Sales 2020 4,89x
Capitalization 233 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 45,1 $
Spread / Average Target 7,4%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-4.54%233 461
JOHNSON & JOHNSON7.03%368 416
ROCHE HOLDING LTD.9.84%228 186
NOVARTIS13.31%210 460
MERCK AND COMPANY5.98%208 495
ABBVIE-11.50%120 617